Karen Knudsen: Only 1/3 of patients receive 1L treatment intensification with an AR pathway inhibitor and/or docetaxel
Karen Knudsen shared on LinkedIn:
“Prostate cancer remains the second leading cause of cancer-related deaths in the United States—a sobering reality that underscores the need to provide men with metastatic disease the most advanced and effective care available.
Yet, a recent survey of physician practices exposes a critical treatment gap. Despite pivotal trials and clear guidelines recommending doublet or triplet regimens as the standard of care for metastatic castration-sensitive prostate cancer (mCSPC), only ~1/3 of patients receive first-line treatment intensification with an androgen receptor (AR) pathway inhibitor and/or docetaxel.
As Agarwal et al. noted, ‘bivariate analysis showed that physicians cited ‘This is what is recommended in the guidelines’ as a reason for treatment choice in over half of patients who were not prescribed treatment intensification (53.5%), which highlights a lack of understanding of guidelines and a need for education.’
We have a shared responsibility to bridge this gap. Let’s commit to better education, alignment with guidelines, and ensuring that every patient has access to the best possible care. Together, we can change these statistics and improve outcomes for men battling prostate cancer.”
Authors:
Karen E. Knudsen is the Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health.
She also served as president for the Association of American Cancer Institutes (AACI) and on the board of directors of the American Association for Cancer Research (AACR). She serves on the board of advisors for the National Cancer Institute, on 12 external advisory boards for NCI-designated cancer centers and on Exai Bio.
She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023